Changes of Platelet Function and Blood Clotting in Diabetes Mellitus

G F Gensini; R Abbate; S Favilla; G G Neri Serneri

doi:10.1055/s-0038-1656989

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1979; 42(03): 983-993
DOI: 10.1055/s-0038-1656989

Original Article

Schattauer GmbH Stuttgart

Changes of Platelet Function and Blood Clotting in Diabetes Mellitus

Authors

G F Gensini

The Istituto di Patologia Medica II – Universitä di Firenze (Direttore: Prof. G. G. Neri Serneri) Consiglio Nazionale delle Ricerche – Rome – Italy. Program of Preventive Medicine (Project Atherosclerosis)
R Abbate

The Istituto di Patologia Medica II – Universitä di Firenze (Direttore: Prof. G. G. Neri Serneri) Consiglio Nazionale delle Ricerche – Rome – Italy. Program of Preventive Medicine (Project Atherosclerosis)
S Favilla

The Istituto di Patologia Medica II – Universitä di Firenze (Direttore: Prof. G. G. Neri Serneri) Consiglio Nazionale delle Ricerche – Rome – Italy. Program of Preventive Medicine (Project Atherosclerosis)
G G Neri Serneri

The Istituto di Patologia Medica II – Universitä di Firenze (Direttore: Prof. G. G. Neri Serneri) Consiglio Nazionale delle Ricerche – Rome – Italy. Program of Preventive Medicine (Project Atherosclerosis)

Abstract

PDF Download

Summary

We investigated some aspects of blood clotting and of platelet functions in 48 diabetics (12 affected by preclinical diabetes, 15 by clinical diabetes, 21 with complications of diabetes, peripheral vascular disease, ischaemic heart disease or diabetic nephropathy with or without hypertension) in 35 age matched controls and in 7 prediabetics.

Blood clotting has been investigated by gel-chromatography of fibrin soluble complexes, by factor VIII_COAG two stage assay, by factor VIII_AGN electroimmunodiffusion assay and by factor VIII_vWF assay. Platelet functions have been investigated by the determination of circulating platelet aggregates associated with megathrombocytes count, by the malondial- dehyde formation after thrombin and after arachidonic acid. In order to clarify some mechanisms responsible for platelet aggregating plasmatic activity (PAPA) has been investigated by plasmaplatelet cross-matches.

Our results indicate early changes of platelet functions in diabetics, already demonstrable in preclinical diabetes. Platelets are hyperaggregable and produce increased amounts of malondialdehyde after stimulation by thrombin and arachidonic acid, thus suggesting an increased activity of the intraplatelet endoperoxide-thromboxane forming metabolic pathway. An increased concentration of fibrin soluble complexes can be shown in clinical and complicated diabetes whereas in preclinical diabetes the fibrogen complexes concentration is within the normal range.

Factor VIII_vWF results significantly increased in all groups of diabetics, and even in the subjects with prediabetes. Factor VHICoag and Factor VIII_AGN, besides factor VIII_vWF, were significantly increased in clinical and in complicated diabetes. The increased concentration of factor VIII_COAG and of soluble fibrinogen complexes suggest the existence of a hypercoagulable condition in patients with clinical and above all with complicated diabetes.

In these patients a platelet aggregating plasmatic activity can be frequently found. The indication is that platelet hyperaggregation in diabetes is due to various mechanisms. In preclinical diabetes and in some patients with clinical diabetes platelet hyperaggregability is mainly due to a primary platelet hypersensitivity whereas in complicated diabetes, specially when hypercoagulability occurs, platelet hyperaggregation is due to a plasmatic factor related to blood clotting activation.

PDF (455 kb)

References

References
1 Almer LO, Nilsson IM. 1975; On fibrinolysis in diabetes mellitus. Acta Medica Scandinavica 198: 101
2 Almer LO, Pandolfi M, Aberg M. 1975; The plasminogen activator activity of arteries and veins in diabetes mellitus. Thrombosis Research 6: 177
3 Amherdt M, Scherrer JR, Rufener C, Pometta D. 1971; Early capillary changes in diabetes mellitus. Acta Diabetologica Latina 8: 88
4 Badawi H, El-Sawy M, Mikhail M. 1970; Platelets, coagulation and fibrinolysis in diabetic and non-diabetic patients with quiescent coronary heart disease. Angiology 21: 511
5 Bensoussan D, Levy-Toledano S, Passa P. 1975; Platelet hyperaggregation and increased plasma level of von Willebrand Factor in diabetics with retinopathy. Diabetologia 11: 307
6 Bloodworth Jr JM, Molitor DL. 1965; Ultrastructural aspects of human and canine diabetic retinopathy. Investigations in Ophthalmology 4: 1037
7 Boneu B, Corberand J, Plante J, Bierme R. 1977; Evidence that platelet density and volume are not related to aging. Thrombosis Research 10: 475
8 Bridges JM, Dalby AM, Millar JH, Weaver JA. 1965; An effect of D-glucose on platelet stickness. Lancet 1: 75
9 Campbell IW, Dawes J, Fraser DM, Pepper DS, Clarke BF, Duncan LJ F, Cash JD. 1977; Plasma β-Thromboglobulin in diabetes mellitus. Diabetes, 26 12: 1175
10 Colwell A, Halushka PV, Sarji K, Levine J, Sagel J, Nair RM G. 1976; Altered Platelet Function in Diabetes Mellitus. Diabetes 25: 826
11 Denson KW E. 1976. In Biggs R. (Ed.) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications; Oxford and Edinburgh:
12 Dobbie JG, Kwann HC, Colwell J, Suwanwela N. 1973; The role of platelets in the pathogenesis of diabetic retinopathy. Transactions American Academy Ophthalmology Otoryngology 77: 43
13 Fearnley GR, Chakrabarti R, Avis PR D. 1963; Blood fibrinolytic activity in diabetes mellitus and its bearing on heart disease and obesity. British Medical Journal 1: 921
14 Fearnley GR, Chakrabarti R, Hocking ED. 1967; Fibrinolytic effects of diguanides plus ethynoestrenol in occlusive vascular disease. Lancet 2: 1008
15 Fleischman AI, Marvin L, Bierenbaum AS, Somol SL, Watson PB. 1976; In vivo platelet function in diabetes mellitus. Thrombosis Research 9: 467
16 Garg SK, Amorosi EL, Karpatkin S. 1971; Use of the megathrombocytes as an index of megakariocyte number. New England Journal Medicine 284: 11
17 Garg SK, Lackener H, Karpatkin S. 1972; The increased percentage of megathrombocytes in various clinical disorders. Annals of Internal Medicine 77: 361
18 Hafter R, Graeff H. 1975; Molecular aspects of defibrination: in a reptilase-treated case of »dead fetus syndrome«. Thrombosis Research 7: 391
19 Hathorn M, Gilmann T, Campbell GD. 1961; Blood lipids, mucoproteins, and fibrinolytic activity in diabetic Indians and Africans in Natal. Lancet 1: 1314
20 Heath H, Bridgen WD, Canever JV, Pollock J, Hunter PR, Kelsey J, Bloom A. 1971; Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 7: 308
21 Hallem AJ. 1971; Adenosinediphosphate induced platelet adhesiveness in diabetes mellitus with complications. Acta Medica Scandinavica 190: 291
22 Hellem AJ, Skalhegg BA, Odegaard AE. 1964; The platelet adhesiveness in plasma from diabetic and lipemic patients. Sangre 9: 175
23 Karpatkin S, Garg SK, Siskind GW. 1971; Autoimmune thrombocytopenic purpura and the compensated thrombocytolytic state. American Journal of Medicine 51: 1
24 Kraytman M. 1973; Platelet size in thrombocytopenias and thrombocytosis of various origin. Blood 41: 587
25 Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JC. 1972; Increased platelet aggregation in diabetes mellitus. Journal of Laboratory and Clinical Medicine 80: 236
26 Kwaan HC, Colwell JA, Suwanwela N. 1972; Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation. Diabetes 21: 108
27 Laurell CB. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibody. Analytical Biochemistry 15: 45
28 Leone G, Bizzi B, Accorra F, Boni P. 1974. Functional aspects of platelets in diabetes mellitus. In Caprino L, Rossi FC. (Eds.) Platelet Aggregation and Drugs. New York: Academic Press; pages 49
29 MacFarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, Mcpherson J. 1975; A method for assaying von Willebrand factor (ristocetin cofactor). Thrombosis et Diathesis Haemorrhagica 34: 306
30 Malone JI, Van Cader TC, Edwards WC. 1977; Diabetic vascular changes in children Diabetes. 26: 673
31 Matsuo T, Ohki Y. 1977; Classification of platelet aggregation patterns with two ADP solutions (the double-ADP method) and its clinical application to diabetes mellitus. Thrombosis research 11: 453
32 Mayne EE, Bridges JM, Weaver JA. 1970; Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitus. Diabetologia 6: 436
33 Moolten SE, Jiennings PB, Solden A. 1963; Dietary fat and platelet adhesiveness in arteriosclerosis and diabetes. American Journal of Cardiology 11: 290
34 Neri Serneri GG, Abbate R, Gensini GF, Mugnaini C, Lagi A. 1976. Occurrence of a plasmatic aggregating activity in some patients with increased platelet aggregation. European Symposium on Platelet Aggregation, Coagulation, Fibrinolysis and Atherosclerosis. Palermo: 1976
35 Neri Serneri GG, Gensini GF, Abbate R, Prisco D, Mugnaini C. 1976. Soluble fibrinogen complexes and platelet aggregates in patients with history of myocardial infarction and chronic cerebrovascular disorders. A rationale for prophylactic therapy. European Symposium on Platelet Aggregation, Coagulation, Fibrinolysis and Atherosclerosis. Palermo: 1976
36 Neri Serneri GG, Silvestrini E, Gensini GF, Abbate-Gensini R. 1977. Platelet hyperreactivity and decreased survival in chronic cerebrovascular patients. Chronic defibrination syndrome. In Platelet Aggregation in the pathogenesis of cerebrovascular disorders. Proceedings of the Round Conference, Rome 30.10.1974. Springer Verlag: 1977
37 Neri Serneri GG, Gensini GF, Abbate R, Favilla S. 1978 Feature of platelet aggregating plasmatic activity. In press
38 Okuma M, Steiner M, Baldini GM. 1971; Studies on lipid peroxides in platelets. II. Effect of aggregating agents and platelet antibody. Journal of Laboratory and Clinical Medicine 77: 728
39 O’malley BC, Ward JD, Timperly WR, Porter NR, Preston FR. 1975; Platelet abnormalities in diabetic peripheral neuropathy. Lancet 2: 1274
40 Palmberg PF. 1977; Diabetic retinopathy. Diabetes 26: 703
41 Pandolfi M, Nilsson IM, Robertson B, Isacson S. 1967; Fibrinolytic activity of human veins. Lancet 2: 127
42 Pandolfi M, Holmberg L, Turesson I. 1975; Coagulation and platelet adhesion-inducing factor in the endothelium of the retinal vessels. American Journal of Ophthalmology 80: 47
43 Preston FE, Ward JD, Mazzola B, Portez NR, Timperley WR, O’malley BC. 1978; Elevated β-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet 1: 238
44 Sagel J, Colwell JA, Crook L, Laimins M. 1975; Increased platelet aggregation in early diabetes mellitus. Annals of Internal Medicine 82: 733
45 Shaw S, Pegrum GD, Wolff S, Ashton WL. 1967; Platelet adhesiveness in diabetes mellitus. Journal of Clinical Pathology 20: 845
46 Siperstein MD. 1971; Quantitation of diabetic microangiopathy: practical implications. Acta Diabetologica Latina 8: 391
47 Szirtes M. 1970; Platelet aggregation in diabetes mellitus. Advances in Cardiology 4: 179
48 Timperley WR, Ward JD, Preston FE, Duckworth T, O’malley BC. 1975; A reassesment of small vessel disease in diabetic neuropathy. Diabetologia 11: 379
49 Waitzman MB, Colley AM, Nardelli-Olkowska K. 1977; Metabolic approaches to studies on diabetic microangiopathy. Diabetes 26 5: 510
50 Wu KK, Hoak JC. 1974; A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 2: 924